The second meta-analysis in 77,485 people from 28 randomized clinical trials showed that in people with type 2 diabetes, overweight, and obesity, treatment with GLP-1 receptor agonists was associated with a significant reduction of 14% in the relative risk, while separate medications, semaglutide, liraglutide, and dulaglutide, were associated with a reduction in the relative risk of 18%, 14%, and 18% for overall respiratory disease. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.